Sanofi
Sanofi says its RA drug bested Humira in Phase III study
March 11, 2016Medical Communications, Research and Development Humira, Regeneron, Sanofi
Sanofi and its R&D arm Regeneron Pharmaceuticals say their monoclonal antibody sarilumab outperformed AbbVie’s Humira in treating the symptoms of …
Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment
March 4, 2016Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2
Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …
FDA to decide on Sanofi diabetes combo
February 22, 2016Research and Development, Sales and Marketing Lantus, Sanofi
Sanofi will be looking to August for a decision on its new type 2 diabetes combo LixiLan (lixisenatide and Lantus), …
NICE rejects cholesterol drug Praluent in draft guidance
February 8, 2016Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol
NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …
Sanofi plans R&D jobs cuts in France
February 3, 2016Manufacturing and Production, Research and Development Sanofi, Teva, cuts, job losses, olivier brandicourt, redundancies
Sanofi chief executive Olivier Brandicourt is reported to be planning hundreds of job cuts across the firm’s base in France, …
Sanofi expands Iranian presence with memorandum agreement
January 29, 2016Manufacturing and Production, Medical Communications Iran, Sanofi, Serge Weinberg
Sanofi has become the latest pharmaceutical company to expand its presence in post-sanctions Iran, signing a memorandum of co-operation with …
GSK and Sanofi considering developing Zika vaccine
January 26, 2016Manufacturing and Production GSK, Sanofi, World Health Organisation, Zika virus, microcephaly
Pharma companies Sanofi and GSK are reviewing the possibility of using their respective inoculation technologies to develop a vaccine for …
Sanofi seals double oncology research deals
January 11, 2016Research and Development, Sales and Marketing Sanofi, Warp Drive Bio, antibodies, collaboration, immuno-oncology, research
Sanofi has signed two separate research agreements for €1.2 billion, which will give the French firm licensing rights to potential …
FDA review for Sanofi and Regeneron’s biologic arthritis drug
January 8, 2016Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab
The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …
Sanofi abandons MannKind’s failed inhalable insulin
January 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afrezza, Mannkind, Sanofi, insulin
Sanofi is to exit a licensing and co-marketing deal with MannKind for the inhalable insulin Afrezza, after disappointing sales figures …
FDA approves Lilly/Boehringer Lantus biosimilar
December 17, 2015Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly
The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …
Pharma giants Sanofi and Boehringer negotiate deal to swap assets
December 15, 2015Business Services, Manufacturing and Production, Sales and Marketing Andreas Barner, Boehringer, Boehringer Ingelheim, Merial, Sanofi, olivier brandicourt
Two of the world’s biggest pharma companies – Sanofi and Boehringer Ingelheim – have entered into exclusive negotiations to swap …
Sanofi buys in new diabetes drug
November 6, 2015Medical Communications, Research and Development, Sales and Marketing Lexicon Pharma, SGLT2, SGLT2 inhibitors, Sanofi, sotagliflozin
Sanofi has paid an initial $300 million for collaboration and license agreement to develop sotagliflozin, one of a newer class …
Brandicourt sets out Sanofi’s long-term vision
November 6, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, olivier brandicourt, pharma strategy
Sanofi has pledged to plough the money saved from its business restructure into R&D investment, to bring 18 new products …
Sanofi and Hanmi partner to create long-acting diabetes treatments
November 5, 2015Manufacturing and Production, Research and Development Korea, Sanofi, diabetes, hanmi
Sanofi and Hanmi Pharmaceutical have announced a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments. Korea’s …
Latest content
Five Facts about cardiovascular disease
